Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma

• Published in: International urology and nephrology Vol. 32; no. 2; pp. 275 - 278
• Main Authors: Kurtman, C, Celebioğlu, B, Göğüş, O, Andrieu, M N
• Format: Journal Article
• Language: English
• Published: Netherlands Springer Nature B.V 2000
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radiotherapy - methods; Survival Rate
• ISSN: 0301-1623; 1573-2584
• DOI: 10.1023/A:1007174213087

The current study was undertaken to evaluate the Prostate Specific Antigen (PSA) relapse free survival and the prognostic factors in a total of 38 patients with stages of T2a-b, N0, M0 prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT). Mean 69.63 Gy was given with 3D-CRT, the mean follow up time was 13.89 months, and the mean prebiopsied PSA level was 25.12 ng/ml. The 2-year PSA relapse free survival was 47.37% for the entire group. The 2-year PSA relapse free survival rates were 100% and 44.74% for the patients with Gleason score < or = 7 and greater than 7 (p < or = 0.05). Patients with prebiopsied PSA level < or = 10 ng/ml and the stages of T2a or T2b did not show any significant differences (p > or = 0.05). Although the few case number and short term follow up, in this study 3D-CRT was a new effective technique to prostate cancer for our institutes and the Gleason score was important predictor of PSA relapse free survival.